3.72

2.87% -0.11

After Hours: 3.72

Evaxion Biotech A/S ADR (EVAX)

Overview News Price History Option Chain Why EVAX Down? Discussions Forecast

Evaxion Biotech A/S ADR stock is currently priced at $3.72, with a 24-hour trading volume of 6,759. It has seen a -2.87% decreased in the last 24 hours and a -9.49% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $3.83 pivot point. If it approaches the $3.70 support level, significant changes may occur.

Previous Close:

$3.83

Open:

$3.8

24h Volume:

6,759

Market Cap:

$20.13M

Revenue:

Net Income/Loss:

$-24.47M

P/E Ratio:

-3.7959

EPS:

-0.98

Net Cash Flow:

$-24.56M

1W Performance:

+0.00%

1M Performance:

-9.49%

6M Performance:

-49.04%

1Y Performance:

-77.45%

1D Range:

$3.72

$3.8231

52W Range:

$2.8243

$18.50

Evaxion Biotech A/S ADR Stock (EVAX) Company Profile

Name

Evaxion Biotech A/S ADR

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

45 53 53 18 50

Address

Dr. Neergaards Vej, 5th Floor, Horsholm

Employee

Twitter

Next Earnings Date

2024-05-29

Latest SEC Filings

EVAX's Discussions on Twitter

Evaxion Biotech A/S ADR Stock (EVAX) Latest News

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

GlobeNewswire Inc.

Evaxion und nicht offengelegter Kooperationspartner veröffentlichen vielversprechende Ergebnisse für EVX-B1-Impfstoff-Antigene gegen Staphylococcus aureus-Infektionen

GlobeNewswire Inc.

Evaxion Biotech A/S ADR Stock (EVAX) Financials Data

Evaxion Biotech A/S ADR (EVAX) Net Income 2024

EVAX net income (TTM) was -$24.47 million for the quarter ending September 30, 2023, a +0.79% increase year-over-year.

Evaxion Biotech A/S ADR (EVAX) Cash Flow 2024

EVAX recorded a free cash flow (TTM) of -$24.56 million for the quarter ending June 30, 2022, a -23.76% decrease year-over-year.

Evaxion Biotech A/S ADR (EVAX) Earnings per Share 2024

EVAX earnings per share (TTM) was -$9.50 for the quarter ending September 30, 2023, a +12.04% growth year-over-year.

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.